AG
BCLI

Advisor Group’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Advisor Group’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$28K Hold
440
– – ﹤0.01% 3762
2019
Q3 		$26K Hold
440
– – ﹤0.01% 3788
2019
Q2 		$26K Buy
440
+133
+43% +$7.74K ﹤0.01% 3792
2019
Q1 		$20K Buy
307
+67
+28% +$3.81K ﹤0.01% 3972
2018
Q4 		$12K Hold
240
– – ﹤0.01% 4091
2018
Q3 		$13K Buy
240
+7
+3% +$423 ﹤0.01% 4117
2018
Q2 		$14K Buy
233
+66
+40% +$3.88K ﹤0.01% 3899
2018
Q1 		$8K Hold
167
– – ﹤0.01% 4192
2017
Q4 		$10K Buy
167
+34
+26% +$2.03K ﹤0.01% 4071
2017
Q3 		$8K Buy
133
+33
+33% +$2.14K ﹤0.01% 4072
2017
Q2 		$6K Hold
100
– – ﹤0.01% 4155
2017
Q1 		$6K Hold
100
– – ﹤0.01% 4017
2016
Q4 		$4K Hold
100
– – ﹤0.01% 3999
2016
Q3 		$4K Hold
100
– – ﹤0.01% 3965
2016
Q2 		$3K Buy
+100
New +$3.51K ﹤0.01% 3956

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Advisor Group's BCLI Position: Q4 2019 in Review

Advisor Group held its BRAINSTORM CELL THERAPUTC (BCLI) position steady in Q4 2019 at 440 shares worth $28K. The position accounts for ﹤0.01% of the portfolio, ranked #3762.

Advisor Group first reported a position in BCLI in Q2 2016 and has held it in 15 quarters since. 43 funds tracked by Wall St. Rank hold BCLI as of Q4 2019.

  • Advisor Group held 440 shares of BRAINSTORM CELL THERAPUTC worth $28K as of Q4 2019.
  • Advisor Group left its BRAINSTORM CELL THERAPUTC share count unchanged in Q4 2019.
  • BRAINSTORM CELL THERAPUTC made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #3762 holding.
  • Advisor Group first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2016 and has held it in 15 quarters since.
  • 43 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.